SuperworthTravere Therapeutics shares outstanding TVTX
Diluted shares outstanding, averaged over each quarter, from 2011.
- Latest quarter, to Jun 30, 2026
- 93.5M
- On a year earlier
- +5.1%
- more shares
Travere Therapeutics had 93.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 5.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 90.3M | +9% |
| FY2024 | 83.1M | +9% |
| FY2023 | 76.5M | +19% |
| FY2022 | 64.2M | +4% |
| FY2021 | 61.6M | +20% |
| FY2020 | 51.3M | +19% |
| FY2019 | 43M | +4% |
| FY2018 | 41.3M | +3% |
| FY2017 | 40.2M | +6% |
| FY2016 | 37.8M | +4% |
| FY2015 | 36.3M | +48% |
| FY2014 | 24.5M | +34% |
| FY2013 | 18.4M | +17129% |
| FY2012 | 106.7K | −98% |
| FY2012 | 5.6M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 93.5M | +5% | |
| Q1 FY26 | 91.9M | +4% | |
| Q4 FY25 | 90.3M | +9% | |
| Q3 FY25 | 102.6M | +32% | |
| Q2 FY25 | 88.9M | +15% | |
| Q1 FY25 | 88.4M | +15% | |
| Q4 FY24 | 83.1M | +9% | |
| Q3 FY24 | 77.8M | +2% | |
| Q2 FY24 | 77.5M | +2% | |
| Q1 FY24 | 77.1M | +13% | |
| Q4 FY23 | 76.5M | +19% | |
| Q3 FY23 | 76.3M | +19% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Travere Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.